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Abstract: Central serous chorioretinopathy (CSCR) is an idiopathic ocular condition – ﬁ  rst 
described in 1866 – that is well known to ophthalmologists. It is less well known to other prac-
titioners. Glucocorticoids have been strongly implicated as a pathogenic factor. We report three 
patients who developed CSCR following exogenous administration of corticosteroid. Because 
our patients did not suspect the use of corticosteroid to be important or causative, they did not 
volunteer the historical detail, and admitted to exogenous corticosteroid injection only with 
intensive questioning. For their part, physicians should be cognizant of the risk of corticosteroid-
induced CSCR, particularly in patients with a prior history of the potentially sight-threatening 
disease. The development of CSCR is an important iatrogenic and often unrecognized side 
effect of exogenously administered corticosteroid.
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CSCR is an idiopathic ocular condition characterized by pathologic accumulation 
of ﬂ  uid at the posterior pole of the fundus, creating a localized retinal detachment 
(Klais et al 2006). Patients present with decreased vision, metamorphopsia and/or 
chromatopsia when the macular retina is involved, but are generally asymptomatic 
with extrafoveal, eccentric lesions. The disease typically affects young and middle-
aged adults, with men more commonly affected than women. Most cases resolve 
spontaneously with visual recovery, but recurrences are common and may lead to 
permanent visual loss.
The pathogenesis of the disease, although incompletely understood, has been 
attributed to dysfunction in the retinal pigment epithelium (RPE) (Spitznas 1986), 
the choroid (Piccolino and Borgia 1994), or both. Glucocorticoids have been 
strongly implicated as a pathogenic factor, since CSCR occurs both in conditions 
of endogenous hypercortisolism such as Cushing’s disease and in the setting of 
exogenously administered glucocorticoids (Bouzas et al 2002). CSCR may develop 
when exogenous corticosteroid is administered by any number of routes – including 
systemic (oral, intravenous), local (intramuscular, intraarticular, epidural) and topical 
(inhalational, intranasal, and dermatologic; Karadimas et al 2004). Accordingly, 
some have argued that CSCR should be added to the list of ocular complications 
of glucocorticoids, administered by any route (Bouzas et al 2002; Karadimas and 
Bouzas 2004).
We report three patients who developed CSCR with exogenous administration 
of steroid. Of particular note, all 3 patients initially denied recent corticosteroid 
use. This retrospective study was approved by the Institutional Review Board 
of Mayo Foundation, and was Health Insurance Portability and Accountability 
Act-compliant.Clinical Ophthalmology 2008:2(1) 200
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Brief report of cases
Case 1
A 67-year-old male presented with a four-week history of 
blurred vision in the left eye. The patient initially presented 
to his primary-care physician who attributed the visual 
decline to a cataract. Past medical history was signiﬁ  cant 
for adequately controlled hypertension.
On referral to ophthalmology, the patient denied any 
form of corticosteroid use. After intensive questioning, he 
admitted to having an intramuscular corticosteroid injection 
for shoulder pain 6 weeks prior to the visit.
Best corrected visual acuity was 20/20 right eye and 20/60 
left eye. On funduscopy, there were subtle RPE changes in 
both maculas, and subretinal ﬂ  uid in the left eye temporal 
to the fovea. A ﬂ  uorescein angiogram (FA) demonstrated 
an irregular patch of progressive hyperﬂ  uorescence within 
the area of subretinal ﬂ  uid in the left eye, consistent with 
CSCR.
The patient was initially observed. At 10-day follow-up, 
vision in the left eye had decreased to 20/200. Laser photo-
coagulation was performed. Ten days post-treatment, vision 
had improved to 20/50, and subretinal ﬂ  uid had decreased 
on funduscopic exam.
Case 2
A 40-year-old normotensive male related a two-day history 
of a central shadow in his right eye. Past eye history was 
remarkable for a previous episode of CSCR in the right eye 
that spontaneously resolved 18 months before the current 
episode. Medical history was signiﬁ  cant for seasonal aller-
gies. He initially denied corticosteroid use, but subsequently 
remembered receiving a corticosteroid injection for an exac-
erbation of allergies one month prior to presentation.
Best corrected visual acuity was 20/20 in both eyes. On 
dilated funduscopy, there was a 1.5 disc-diameter area of 
subretinal ﬂ  uid in the right eye extending from the superior 
edge of the fovea. On FA, there was a pinpoint area of 
progressive hyperﬂ  uorescence within the region of subretinal 
ﬂ  uid. A diagnosis of recurrent CSCR was made. No treatment 
was advised, given the presenting vision.
Case 3
A 72-year-old male presented with a complicated eye his-
tory. The patient was pseudophakic in both eyes. He had 2 
prior episodes of CSCR in the left eye – in 1992 and again in 
1999 – both of which remitted spontaneously without visual 
compromise. In January 2006, a rhegmatogenous retinal 
detachment and a large choroidal melanoma were diagnosed 
in the right eye. The melanoma was treated elsewhere with 
brachytherapy in March 2006.
The patient presented to our institution in May 2006 
for continuing followup of the melanoma in his right eye. 
There were no visual concerns in his left eye. Past medical 
history was signiﬁ  cant for treated hypertension and thyroid-
replacement therapy. Only on intensive questioning did the 
patient admit to having two recent epidural corticosteroid 
injections for low back pain, 4 to 7 weeks prior to his Mayo 
Clinic visit.
On presentation, visual acuity was count ﬁ  ngers right 
eye and 20/20 left eye. There were well positioned posterior 
chamber intraocular lenses in both eyes. In the right eye, 
there was a large ciliochoroidal melanoma, and a ﬁ  brovas-
cular and total retinal detachment. In the fellow eye, there 
were ﬁ  ne pigment changes under the fovea. An optical 
coherence tomography of the left macula was obtained: the 
paramacular neurosensory retina was elevated, consistent 
with active CSCR. No treatment was undertaken, given the 
asymptomatic nature of the lesion.
Discussion
Of a number of risk factors that predispose to the develop-
ment of CSCR, glucocorticoids have been strongly impli-
cated as a pathogenic factor (Haimovici et al 2004). The 
prevalence of exogenous administration of glucocorticoid in 
patients developing CSCR has been reported at less than 10 
percent in 3 large retrospective studies (Lowder et al 1981; 
Wakakura et al 1987; Tittl et al 1999). In 2 recent prospec-
tive studies, prevalence was reported at 29% and 52%, and in 
each study was statistically signiﬁ  cant compared with case-
matched controls (Carvalho-Recchia et al 2002; Karadimas 
and Bouzas 2004). As reviewed by Bouzas and colleagues 
(2002), CSCR may develop from a few days to several years 
after the initiation of exogenous corticosteroid, and in doses 
as low as 10–15 mg orally per day. The elderly population 
is particularly vulnerable to small amounts of corticosteroid 
(Koyama et al 2004).
Primary-care providers who routinely administer exog-
enous corticosteroid should be aware of the glucocorti-
coids – CSCR connection. Case 1 highlights that accurate 
diagnosis may be elusive without an index of suspicion. 
Providers should be mindful that CSCR may develop or 
recur with exogenous corticosteroid administered at low 
doses and by any route.
Our report underscores the need for careful history tak-
ing on the part of both primary- and eye-care providers. 
Primary care should elicit a careful eye history before the Clinical Ophthalmology 2008:2(1) 201
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administration of exogenous corticosteroid. In particular, 
inquiries of a prior history of CSCR or episodes of blurred 
central vision should be made. Cases 2 and 3 demonstrate 
that patients with prior disease may be given exogenous 
corticosteroid unwittingly, and may then go on to develop 
recurrent CSCR. For the ophthalmologist’s part, queries of a 
prior history of corticosteroid use in any form should be made 
when a patient presents with CSCR. Since patients may not 
view one-time or pulsed administration – such as an intra-
muscular injection – as corticosteroid use worth reporting 
or in any way related to their current eye problem, they may 
fail to mention it during medication inventory. All three case 
reports demonstrate that patients with CSCR may not readily 
volunteer information of recent corticosteroid use. To more 
fully capture corticosteroid use, the ophthalmologist should 
review the past medical history, inquiring speciﬁ  cally about 
conditions that are often treated with corticosteroid (eg, aller-
gies, asthma, joint pain). Without a complete log of recent 
medications, exogenous corticosteroid may be neglected, 
leading to a general underreporting of corticosteroid-induced 
cases of CSCR.
Finally, a heightened awareness of the corticosteroid – 
CSCR connection on the part of the primary provider and the 
patient will insure a more fully informed consent. Aware of 
the risk of new or recurrent CSCR, the provider should con-
vey that either event – but particularly recurrent disease – can 
lead to permanent visual loss.
In summary, this report reinforces CSCR as a potential 
ocular complication of corticosteroid therapy in any form. 
It emphasizes that patients may not readily volunteer 
corticosteroid use – especially when given a single dose in 
a form such as intramuscular injection – and underscores 
the need for a careful history and inventory of recent 
medications. Finally, it serves to heighten awareness of 
primary-care providers to this potentially sight-threatening 
ocular complication.
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